# Methotrexate - Inadequate Response Device Sub-Study

> **NCT01173120** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 62 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DEVICE:** Abatacept combination product (ACP)

## Key facts

- **NCT ID:** NCT01173120
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-02
- **Final completion:** 2010-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2012-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01173120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01173120, "Methotrexate - Inadequate Response Device Sub-Study". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01173120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*